| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Growth Factor and Cell Differentiation Laboratory, University Bordeaux I, 33 405 Talence, France [P. A., D. B. G., S. L., A. B.]; Department of Histology, Hopital Ramon Y Cajal, 28006 Madrid, Spain [D. R., P. C., F. C.]; and Unité des Cytokines et Développement Lymphoide, Departement dImmunologie, Institut Pasteur, 75 724 Paris, France [J. P. D. S.]
We undertook a series of systematic studies to address the role of fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) activity in tumor growth and angiogenesis. We expressed dominant-negative FGFR2 (FGFR2-DN) or FGFR1 (FGFR1-DN) in glioma C6 cells by using constitutive or tetracycline-regulated expression systems. Anchorage-dependent or independent growth was inhibited in FGFR-DN-expressing cells. Tumor development after xenografting FGFR-DN-expressing cells in immunodeficient mice or after transplantation in rat brain was strongly inhibited. Quantification of microvessels demonstrated a significant decrease in vessel density in tumors derived from FGFR-DN-expressing cells. Furthermore, in a rabbit corneal assay, the angiogenic response after implantation of FGFR-DN-expressing cells was decreased. In tumors expressing FGFR-DN, vascular endothelial growth factor expression was strongly inhibited as compared with control tumor. These results indicate that inhibition of FGF activity may constitute a dominant therapeutic strategy in the treatment of FGF-producing cerebral malignancies and may disrupt both angiogenesis-dependent and -independent signals required for glioma growth and invasion.
This article has been cited by other articles:
![]() |
T. Onguchi, K. Y. Han, J.-H. Chang, and D. T. Azar Membrane Type-1 Matrix Metalloproteinase Potentiates Basic Fibroblast Growth Factor-Induced Corneal Neovascularization Am. J. Pathol., April 1, 2009; 174(4): 1564 - 1571. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fischer, N. Taylor, S. Allerstorfer, M. Grusch, G. Sonvilla, K. Holzmann, U. Setinek, L. Elbling, H. Cantonati, B. Grasl-Kraupp, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition Mol. Cancer Ther., October 1, 2008; 7(10): 3408 - 3419. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Brantley and E. N. Benveniste Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas Mol. Cancer Res., May 1, 2008; 6(5): 675 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Magnusson, A. Dimberg, S. Mellberg, A. Lukinius, and L. Claesson-Welsh FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin Blood, December 15, 2007; 110(13): 4214 - 4222. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. White, K. J. Lavine, and D. M. Ornitz FGF9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network Development, October 15, 2007; 134(20): 3743 - 3752. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-C. Liu, T. Zhang, H. Fukuhara, T. Kuroda, T. Todo, X. Canron, A. Bikfalvi, R. L. Martuza, A. Kurtz, and S. D. Rabkin Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors. Clin. Cancer Res., November 15, 2006; 12(22): 6791 - 6799. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Basile, R. M. Castilho, V. P. Williams, and J. S. Gutkind Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis PNAS, June 13, 2006; 103(24): 9017 - 9022. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Magnusson, R. Ronca, P. Dell'Era, P. Carlstedt, L. Jakobsson, J. Partanen, A. Dimberg, and L. Claesson-Welsh Fibroblast Growth Factor Receptor-1 Expression Is Required for Hematopoietic but not Endothelial Cell Development Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 944 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rousseau, F. Larrieu-Lahargue, S. Javerzat, F. Guilhem-Ducleon, F. Beermann, and A. Bikfalvi The tyrp1-Tag/tyrp1-FGFR1-DN Bigenic Mouse: A Model for Selective Inhibition of Tumor Development, Angiogenesis, and Invasion into the Neural Tissue by Blockade of Fibroblast Growth Factor Receptor Activity Cancer Res., April 1, 2004; 64(7): 2490 - 2495. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Magnusson, C. Rolny, L. Jakobsson, C. Wikner, Y. Wu, D. J. Hicklin, and L. Claesson-Welsh Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development J. Cell Sci., March 15, 2004; 117(8): 1513 - 1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Huang, Y. Lin, Q. Shi, L. Flowers, S. Ramachandran, I. R. Horowitz, S. Parthasarathy, and R.-P. Huang Enhanced Protein Profiling Arrays with ELISA-Based Amplification for High-Throughput Molecular Changes of Tumor Patients' Plasma Clin. Cancer Res., January 15, 2004; 10(2): 598 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-m. He, Y.-q. Wei, L. Tian, X. Zhao, J.-m. Su, L. Yang, Y. Lu, B. Kan, Y.-y. Lou, M.-j. Huang, et al. Inhibition of Tumor Growth with a Vaccine Based on Xenogeneic Homologous Fibroblast Growth Factor Receptor-1 in Mice J. Biol. Chem., June 6, 2003; 278(24): 21831 - 21836. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hagedorn, L. Zilberberg, J. Wilting, X. Canron, G. Carrabba, C. Giussani, M. Pluderi, L. Bello, and A. Bikfalvi Domain Swapping in a COOH-terminal Fragment of Platelet Factor 4 Generates Potent Angiogenesis Inhibitors Cancer Res., December 1, 2002; 62(23): 6884 - 6890. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Bello, G. Carrabba, C. Giussani, V. Lucini, F. Cerutti, F. Scaglione, J. Landre, M. Pluderi, G. Tomei, R. Villani, et al. Low-dose Chemotherapy Combined with an Antiangiogenic Drug Reduces Human Glioma Growth in Vivo Cancer Res., October 1, 2001; 61(20): 7501 - 7506. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |